<DOC>
	<DOCNO>NCT02148328</DOCNO>
	<brief_summary>The purpose study examine safety tolerability administration trivalent quadrivalent cell-based virosomal influenza vaccine healthy adult .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity Study Cell-based Virosomal Influenza Vaccine Healthy Adults</brief_title>
	<detailed_description>This double-blind randomized study healthy adult . The duration study approximately 90 day per participant . The study include 4 visit : Day 1 ( vaccination ) , Day 4 , Day 22 day 90 ( Follow-up visit ) . Safety tolerability assess rate solicit , unsolicited , serious adverse event .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female adult Body Mass Index &lt; = 30 kilogram per square meter ( kg/m^2 ) Written informed consent Vaccination 2013/2014seasonal influenza vaccine and/or receipt vaccine 4 week precede receipt study vaccine and/or vaccination plan within 3 week study vaccine Diagnosis ( rapid test , perform clinic/hospital laboratory ) laboratoryconfirmed influenza 2013/2014 season Acute exacerbation bronchopulmonary infection ( cough , sputum , lung finding ) acute disease Acute febrile illness ( great equal 38.0 celcius ) Pregnancy assess urine pregnancy test vaccination , lactation . Women childbearing potential ( , surgically sterilized/hysterectomized postmenopausal 2 year ) exclude one follow criterion meet : 1 ) . Intention become pregnant course study donate egg ( ovum , oocytes ) purpose assist reproduction 2 ) . If heterosexually active , use willing continue use medically reliable method contraception entire study duration ( 90 day ) . A medically reliable method contraception include oral contraceptive preparation ( example pill ) , hormonal implant , progestative injection , patch contraceptive formulation , intrauterine device , concomitant use barrier method spermicide , another method consider sufficiently reliable investigator individual case</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza</keyword>
	<keyword>Prevention</keyword>
	<keyword>Safety</keyword>
</DOC>